MX2021014113A - Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents
Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).Info
- Publication number
- MX2021014113A MX2021014113A MX2021014113A MX2021014113A MX2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inhibitors
- quinazoline derivatives
- relates
- amino quinazoline
- Prior art date
Links
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177604 | 2019-05-31 | ||
| EP19201168 | 2019-10-02 | ||
| PCT/EP2020/064914 WO2020239952A1 (en) | 2019-05-31 | 2020-05-28 | Amino quinazoline derivatives as p2x3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014113A true MX2021014113A (es) | 2021-12-10 |
Family
ID=70861506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014115A MX2021014115A (es) | 2019-05-31 | 2020-05-28 | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). |
| MX2021014113A MX2021014113A (es) | 2019-05-31 | 2020-05-28 | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014115A MX2021014115A (es) | 2019-05-31 | 2020-05-28 | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12466820B2 (enExample) |
| EP (2) | EP3976179A1 (enExample) |
| JP (3) | JP7644029B2 (enExample) |
| KR (2) | KR20220016498A (enExample) |
| CN (3) | CN113891745B (enExample) |
| AU (2) | AU2020281923A1 (enExample) |
| BR (2) | BR112021022099A2 (enExample) |
| CA (2) | CA3139018A1 (enExample) |
| CL (1) | CL2021003165A1 (enExample) |
| CO (1) | CO2021017031A2 (enExample) |
| GE (2) | GEP20257823B (enExample) |
| IL (1) | IL288405A (enExample) |
| MA (2) | MA56021A (enExample) |
| MX (2) | MX2021014115A (enExample) |
| PE (1) | PE20220934A1 (enExample) |
| PH (1) | PH12021552881A1 (enExample) |
| SA (1) | SA521430920B1 (enExample) |
| SG (1) | SG11202112187YA (enExample) |
| WO (2) | WO2020239952A1 (enExample) |
| ZA (1) | ZA202108273B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3976597T3 (fi) | 2019-05-31 | 2024-09-25 | Janssen Pharmaceutica Nv | Nf-kb:tä indusoivan kinaasin pienimolekyylisiä estäjiä |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| MA56021A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| MX2021014116A (es) * | 2019-05-31 | 2021-12-10 | Chiesi Farm Spa | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). |
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| EP4234548A4 (en) * | 2020-10-20 | 2024-10-23 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, ITS PREPARATION METHOD AND ITS APPLICATION |
| JP2023550830A (ja) * | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体 |
| JP2023550840A (ja) * | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としてのアミノキナゾリン誘導体 |
| CN112661803A (zh) * | 2020-12-17 | 2021-04-16 | 上海药明康德新药开发有限公司 | DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法 |
| US20240239764A1 (en) * | 2020-12-22 | 2024-07-18 | Mekanistic Therapeutics | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
| CN114907284B (zh) * | 2021-02-10 | 2023-11-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| CN115677601B (zh) * | 2021-07-29 | 2025-06-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| WO2024235225A1 (zh) * | 2023-05-15 | 2024-11-21 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并环类抑制剂及其制备方法和应用 |
| TW202502343A (zh) | 2023-05-22 | 2025-01-16 | 義大利商吉斯藥品公司 | 胺基喹唑啉衍生物之鹽 |
| AR132737A1 (es) | 2023-05-22 | 2025-07-23 | Chiesi Farm Spa | Proceso e intermedios para la preparación de un inhibidor p2x3 |
| WO2025101598A1 (en) * | 2023-11-07 | 2025-05-15 | Zeno Management, Inc. | Bi-cyclic pyrimidine compounds, methods and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH31122A (en) * | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| RU2422441C2 (ru) * | 2004-03-05 | 2011-06-27 | Ф.Хоффманн-Ля Рош Аг | Диаминопиримидины в качестве антагонистов рецепторов р2х3 |
| CA2618340C (en) * | 2005-08-15 | 2013-11-19 | F.Hoffmann-La Roche Ag | Piperidine and piperazine derivatives as p2x3 antagonists |
| EP1924264B9 (en) | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| CN103159692B (zh) | 2006-06-29 | 2015-03-18 | 弗·哈夫曼-拉罗切有限公司 | 四唑取代的芳基酰胺类 |
| ES2566387T3 (es) | 2007-04-02 | 2016-04-12 | Evotec Ag | Compuestos heterocíclicos condensados de pirid-2-ilo, y composiciones y usos de los mismos |
| PT2139334E (pt) | 2007-04-17 | 2013-10-02 | Evotec Ag | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos |
| US8946439B2 (en) | 2008-02-29 | 2015-02-03 | Evotec Ag | Amide compounds, compositions and uses thereof |
| CA2737038A1 (en) | 2008-09-18 | 2010-03-25 | Evotec Ag | Amide compounds, compositions and uses thereof |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CA2886139A1 (en) * | 2012-12-27 | 2014-07-03 | F. Hoffmann-La Roche Ag | Comt inhibitors |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| JPWO2016084922A1 (ja) | 2014-11-28 | 2017-09-07 | 塩野義製薬株式会社 | １，２，４−トリアジン誘導体およびその医薬組成物 |
| WO2016088838A1 (ja) | 2014-12-04 | 2016-06-09 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
| SI3587417T1 (sl) | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il substituirani benzamidi |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| EP3355889B1 (en) * | 2015-09-29 | 2023-02-15 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| CA3006300C (en) * | 2015-11-25 | 2024-02-27 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| ES2800339T3 (es) | 2016-06-30 | 2020-12-29 | Gilead Sciences Inc | 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos |
| JP7101165B2 (ja) | 2016-08-15 | 2022-07-14 | ニューファーマ， インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
| CN110167928A (zh) | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018204775A1 (en) * | 2017-05-05 | 2018-11-08 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| MX2021014116A (es) | 2019-05-31 | 2021-12-10 | Chiesi Farm Spa | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). |
| MA56021A (fr) * | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
-
2020
- 2020-05-28 MA MA056021A patent/MA56021A/fr unknown
- 2020-05-28 JP JP2021570930A patent/JP7644029B2/ja active Active
- 2020-05-28 EP EP20728765.7A patent/EP3976179A1/en active Pending
- 2020-05-28 MX MX2021014115A patent/MX2021014115A/es unknown
- 2020-05-28 PE PE2021001962A patent/PE20220934A1/es unknown
- 2020-05-28 EP EP20728766.5A patent/EP3976180A1/en active Pending
- 2020-05-28 CN CN202080039837.0A patent/CN113891745B/zh active Active
- 2020-05-28 KR KR1020217043072A patent/KR20220016498A/ko active Pending
- 2020-05-28 PH PH1/2021/552881A patent/PH12021552881A1/en unknown
- 2020-05-28 GE GEAP202015818A patent/GEP20257823B/en unknown
- 2020-05-28 CN CN202080040266.2A patent/CN114269432B/zh active Active
- 2020-05-28 BR BR112021022099A patent/BR112021022099A2/pt unknown
- 2020-05-28 BR BR112021021738A patent/BR112021021738A2/pt unknown
- 2020-05-28 US US17/615,017 patent/US12466820B2/en active Active
- 2020-05-28 CA CA3139018A patent/CA3139018A1/en active Pending
- 2020-05-28 MX MX2021014113A patent/MX2021014113A/es unknown
- 2020-05-28 KR KR1020217043074A patent/KR20220016499A/ko active Pending
- 2020-05-28 SG SG11202112187YA patent/SG11202112187YA/en unknown
- 2020-05-28 GE GEAP202515818A patent/GEAP202515818A/en unknown
- 2020-05-28 JP JP2021570931A patent/JP7641917B2/ja active Active
- 2020-05-28 MA MA056022A patent/MA56022A/fr unknown
- 2020-05-28 WO PCT/EP2020/064914 patent/WO2020239952A1/en not_active Ceased
- 2020-05-28 CN CN202410508911.9A patent/CN118239931A/zh active Pending
- 2020-05-28 WO PCT/EP2020/064913 patent/WO2020239951A1/en not_active Ceased
- 2020-05-28 AU AU2020281923A patent/AU2020281923A1/en active Pending
- 2020-05-28 AU AU2020285336A patent/AU2020285336A1/en active Pending
- 2020-05-28 CA CA3139019A patent/CA3139019A1/en active Pending
- 2020-05-28 US US17/615,056 patent/US20230092892A1/en active Pending
-
2021
- 2021-10-26 ZA ZA2021/08273A patent/ZA202108273B/en unknown
- 2021-11-22 SA SA521430920A patent/SA521430920B1/ar unknown
- 2021-11-25 IL IL288405A patent/IL288405A/en unknown
- 2021-11-29 CL CL2021003165A patent/CL2021003165A1/es unknown
- 2021-12-14 CO CONC2021/0017031A patent/CO2021017031A2/es unknown
-
2025
- 2025-02-27 JP JP2025029719A patent/JP2025098014A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014113A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
| CO2019008986A2 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| CL2020002939A1 (es) | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| UY29840A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| UY35963A (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| MX387125B (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| BR112012007635A2 (pt) | derivados de feniloxadiazol como inibidores de pgds | |
| BR112021020279A2 (pt) | Derivados de piridopirimidinas como inibidores de p2x3 | |
| ZA202308388B (en) | Nasal compositions comprising alcaftadine | |
| MX2021012749A (es) | Inhibidor selectivo de la jak1 cinasa. | |
| MX371178B (es) | Orvepitant para el tratamiento de la tos crónica. | |
| MX2021000270A (es) | Derivados de la tirosina amida como inhibidores de la rho- cinasa. | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2023005803A (es) | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| EA202193300A1 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
| MX2023005865A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
| MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
| CO2023009444A2 (es) | Derivados de dihidrofuropiridina como inhibidores de la rho-cinasa | |
| MX2022004809A (es) | Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc). | |
| MX377199B (es) | Nuevo compuesto aislado a partir de pseudolysimachion rotundum var. subintegrum que contiene cantidades abundantes del ingrediente activo, la composicion que lo comprende para prevenir o tratar la enfermedad alergica, enfermedad inflamatoria, asma o enfermedad pulmonar obstructiva cronica y el uso del mismo. | |
| NZ761390A (en) | Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor |